Date: 2012-02-13
Type of information: Fundraising
Company: Innavirvax (France)
Investors: Pradeyrol Développement(France)
Fa Dièse (France)
FRCI (Fonds Régional de Co-Investissement d’Ile-de-France) (France)
Cap Decisif 2 (France)
G1J (France)
Amount: € 3.7 million
Funding type: financing round
Planned used: The funds will be used to continue InnaVirVax’s development, including achieving clinical Phase I / IIa immunotherapy VAC-3S (See http://biopharmanalyses.fr/clinical-trails/?pageid=403).
Others: InnaVirVax, a biopharmaceutical company specializing in research and development of innovative therapeutic and diagnostic medical conditions related to immune dysregulation, has completed a second financing round for € 3 7 million.This second round hosts Pradeyrol Development, a family office, and Fa Dièse and F Sharp FRCI (Regional Fund Co-Investment Ile-de-France) Investment Funds. They join the previous shareholders of InnaVirVax, CapDecisif and G1J, which increase their support by participating in this second round of financing. The funds will be used to continue InnaVirVax’s development, including achieving clinical Phase I / IIa of immunotherapy VAC-3S.
Therapeutic area: Infectious diseases
